REG - Angle PLC - Change of Adviser

AngleAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250909:nRSI4938Ya&default-theme=true

RNS Number : 4938Y  Angle PLC  09 September 2025

 For immediate release  9 September 2025

 

ANGLE plc ("the Company")

 

APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce that it has
appointed Cavendish Capital Markets Limited as the Company's Nominated Adviser
and Sole Broker with immediate effect.

 

 

 

For further information:

 

 ANGLE plc                                       +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Cavendish (NOMAD and Broker)                    +44 (0) 20 7220 0500

 Geoff Nash / Isaac Hooper (Corporate Finance)

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 FTI Consulting

 Simon Conway, Ciara Martin, Sam Purewal         +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                        +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://protect.checkpoint.com/v2/r01/___https:/angleplc.com/investor-relations/glossary/___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6bzo0NWNkOTlkNDliOTlmNDBjMjE5MmQyMjYwODBkNjJjMDo3OjYwOTM6MDNiYTZjZjg5YTJiZGQ1NGE4YjNhYjdkNzkxZWMyZDQzNTcxNmVjNTllMzdjMTY5NDMzZDgyMGMzMjgxMjliYTpwOlQ6Tg)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system, associated
consumables and assays. The clinical services business is offered through
ANGLE's GCLP-compliant laboratories.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 115 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(https://protect.checkpoint.com/v2/r01/___http:/www.angleplc.com___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6bzo0NWNkOTlkNDliOTlmNDBjMjE5MmQyMjYwODBkNjJjMDo3OmI1YTc6MTFiNjRjMDZiNjQ0YWI4ZDA4OGQ1ZDVjN2FjNzU4YTQzMWY3ZmE1MjliYmQzNWYwMTM3YTY1ZGZhODI0MGY0MDpwOlQ6Tg)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBCGDCXDGDGUI